SCHEMBL1658342

SCHEMBL1658342

COc1cccc(N2CCN(c3ccc(-c4n[nH]c(=O)c5ccccc45)cc3N)CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 9/20 0.53
ROCK2 O75116 6/20 0.53
POLB P06746 2/20 0.52
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
LMNA P02545 1/20 0.52
TSHR P16473 1/20 0.52
PDE4A P27815 1/20 0.49
PDE4B Q07343 1/20 0.49
PDE4C Q08493 1/20 0.49
PDE4D Q08499 1/20 0.49
DHFR P00374 1/20 0.45
DCTPP1 Q9H773 2/20 0.43
TNKS O95271 1/20 0.43
TNKS2 Q9H2K2 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1658864 0.83 ALDH1A1 (0.61) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1658801 0.83 KDM4E (0.64) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1657467 0.83 ALDH1A1 (0.57) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL12909290 0.82 POLB (0.65) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1658238 0.81 KDM4E (0.58) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1657449 0.81 ALDH1A1 (0.53) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL10149736 0.81 POLB (0.64) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL10149809 0.81 POLB (0.64) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1658587 0.81 KDM4E (0.57) ROCK1ROCK2POLBKDM4EALDH1A1
SCHEMBL1658177 0.81 ALDH1A1 (0.57) ROCK1ROCK2POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098304-A1 Small molecule inhibitors of PARP activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-28 US claimed
EP-2214667-A2 SMALL MOLECULE INHIBITORS OF PARP ACTIVITY Angion Biomedica Corp. (US) 2010-08-11 EP claimed
WO-2009054952-A2 SMALL MOLECULE INHIBITORS OF PARP ACTIVITY ANGION BIOMEDICA CORP. (US) 2009-04-30 WO claimed
US-20110098304-A1 Small molecule inhibitors of PARP activity NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098304-A1 Small molecule inhibitors of PARP activity PARP1, PARP11, PARP2 ROCK1 904/4885ROCK2 1184/4885POLB 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.